David Wayne Robinson - 21 Jan 2026 Form 4 Insider Report for OCULAR THERAPEUTIX, INC (OCUL)

Role: Global CCO
Signature: /s/ Todd Anderman, Attorney-in-Fact for David Wayne Robinson
Issuer symbol: OCUL
Transactions as of: 21 Jan 2026
Net transactions value: $0
Form type: 4
Filing time: 26 Jan 2026, 19:15:21 UTC
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Robinson David Wayne	Global CCO	C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD	/s/ Todd Anderman, Attorney-in-Fact for David Wayne Robinson	26 Jan 2026	0002107335

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OCUL	Common Stock	Award	$0	+136,000		$0.000000	136,000	21 Jan 2026	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OCUL	Stock Option (Right to Buy)	Award	$0	+416,000		$0.000000	416,000	21 Jan 2026	Common Stock	416,000	$11.42	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On January 21, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2019 Inducement Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation"). Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter.
F2	This option was granted on January 21, 2026 and vests over four years, with 25% of the shares underlying the option vesting on the one-year anniversary of the reporting person's first date of employment and the remainder vesting in equal monthly installments over the three years after such date.

Content

On January 21, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2019 Inducement Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation"). Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter.

This option was granted on January 21, 2026 and vests over four years, with 25% of the shares underlying the option vesting on the one-year anniversary of the reporting person's first date of employment and the remainder vesting in equal monthly installments over the three years after such date.